A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.
about
Management of Membranous Nephropathy in Western CountriesHistory of Nephrotic Syndrome and Evolution of its TreatmentRepository corticotropin for Chronic Pulmonary Sarcoidosis.Treatment of Sarcoidosis.Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Pharmacological treatment of primary membranous nephropathy in 2016.MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.Adrenocorticotropic hormone analog use for podocytopathiesH.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetesAdrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance.Overview of current and alternative therapies for idiopathic membranous nephropathy.A review of the re-emergence of adrenocorticotrophic hormone therapy in glomerular disease, more than a drug of last resort?Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key IndicationsMembranous nephropathy: thinking through the therapeutic options.Clinical management of pulmonary sarcoidosis.Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Membranous nephropathy-one morphologic pattern with different diseases.Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study.Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.Treatment of primary membranous nephropathy: where are we now?Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent.Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome.Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.Use of synthetic adrenocorticotropic hormone in patients with IgA nephropathy.Pharmacotherapy options for membranous nephropathy
P2860
Q26740477-3C32B818-DBE4-4E1A-960B-AE3F01D48D96Q26745891-AE185AE3-08E7-4337-BDF2-708225A3E2B2Q33705377-15303FE6-1EEB-4016-BD51-1ACE761C5FA7Q34477003-4DAF994B-A527-4630-9BA1-6FF9FCAC5F4FQ35840057-4F003427-6EBA-415D-994C-91F44334001EQ35976834-ACD1D95E-B0AD-4CA8-9834-90C8AA3157CBQ36106413-2B61B5D9-E934-4171-B9F8-BD9DA04CD046Q36980645-D5EDDDC7-4B8D-4B70-98B6-B87F3E679580Q37070458-562916D8-EDE3-4547-86CE-6EB2501EA597Q37072620-ECE8A722-52BE-4BDC-B50F-05D951CCA52CQ37651364-A4E880F1-76F0-423C-93AB-2A1483A18BE7Q38425865-2ABC2660-EDBF-4B8C-9EDE-7508251C3685Q38562318-44928793-BDD1-468D-9A7D-8F3EFC2FB90FQ38667777-65CF9F3F-E134-4BBF-AE9D-B55EAFB92E88Q38703169-2D812806-D98C-4792-AEC1-23AD81CA9665Q38733002-64ED1219-000D-424F-A617-6CCA5A1CE8F9Q38766783-8C2017D1-6DEC-4BF2-B698-33B4CCB30B91Q38858772-EDDC4FC9-BEEB-4F6A-A251-634EEC4D9EB0Q39335899-3655FAC5-F891-4B6C-A8E2-4B177F8CA96FQ39337229-C375E434-85BF-4B06-9F7C-D8A2E7D35B44Q41467613-BE027A1C-AA9C-4706-8F6F-55D26EA6A6B5Q46594445-9861F871-BBCF-4EDD-89DB-77081E418CBAQ47130208-F733812B-8855-4C4A-8A48-C291AA088B8CQ47850601-0AAD71B5-D9E5-4155-92E2-F6C2AAB4C3FBQ50334146-8A472D11-E4B1-4B44-92CB-C33008BA9DF0Q51341198-4FED56CB-92BE-426C-B85A-165B2E339F69Q52670774-AE410457-E78B-429F-AEA7-6735F8A471E2Q55424564-A39AC1E2-74D3-4A0C-ADB5-98134F5F1C90Q57701454-CC216EEF-9ECB-4F83-BF5D-3A2F1AB0C067
P2860
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A pilot study to determine the ...... pathic membranous nephropathy.
@ast
A pilot study to determine the ...... pathic membranous nephropathy.
@en
type
label
A pilot study to determine the ...... pathic membranous nephropathy.
@ast
A pilot study to determine the ...... pathic membranous nephropathy.
@en
prefLabel
A pilot study to determine the ...... pathic membranous nephropathy.
@ast
A pilot study to determine the ...... pathic membranous nephropathy.
@en
P2093
P2860
P356
P1476
A pilot study to determine the ...... opathic membranous nephropathy
@en
P2093
Ayodele Odutayo
Daniel Cattran
Fernando C Fervenza
Heather Reich
Laurence H Beck
Michelle A Hladunewich
Sanjeev Sethi
P2860
P304
P356
10.1093/NDT/GFU069
P407
P577
2014-04-08T00:00:00Z